Israel China Biotechnology (ICB) Ltd (TA:ICB) — Market Cap & Net Worth
Market Cap & Net Worth: Israel China Biotechnology (ICB) Ltd (ICB)
Israel China Biotechnology (ICB) Ltd (TA:ICB) has a market capitalization of $19.47 Million (ILA7.26 Billion) as of May 2, 2026. Listed on the TA stock exchange, this Israel-based company holds position #25094 globally and #367 in its home market, demonstrating a -24.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Israel China Biotechnology (ICB) Ltd's stock price ILA2501.00 by its total outstanding shares 3747710 (3.75 Million). Review how much debt does Israel China Biotechnology (ICB) Ltd carry to assess the company's total debt and financial obligations.
Israel China Biotechnology (ICB) Ltd Market Cap History: 2015 to 2026
Israel China Biotechnology (ICB) Ltd's market capitalization history from 2015 to 2026. Data shows growth from $6.21 Million to $25.13 Million (9.31% CAGR).
Israel China Biotechnology (ICB) Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Israel China Biotechnology (ICB) Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
200.47x
Israel China Biotechnology (ICB) Ltd's market cap is 200.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $6.21 Million | $183.00K | -$4.37 Million | 33.93x | N/A |
| 2016 | $11.21 Million | $96.00K | -$3.85 Million | 116.80x | N/A |
| 2017 | $10.69 Million | $64.00K | -$3.66 Million | 167.04x | N/A |
| 2018 | $4.75 Million | $105.00K | -$3.62 Million | 45.26x | N/A |
| 2019 | $7.03 Million | $139.00K | -$6.41 Million | 50.60x | N/A |
| 2020 | $16.64 Million | $83.00K | -$11.93 Million | 200.47x | N/A |
Competitor Companies of ICB by Market Capitalization
Companies near Israel China Biotechnology (ICB) Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Israel China Biotechnology (ICB) Ltd by market ranking:
- Aju IB Investment Co. Ltd (KQ:027360): Ranked #8309 globally with a market cap of $1.21 Billion USD ( ₩1.78 Trillion KRW).
- Mirae Asset Venture Investment Co. Ltd (KQ:100790): Ranked #8731 globally with a market cap of $1.09 Billion USD ( ₩1.61 Trillion KRW).
- Meitav Dash Investments Ltd (TA:MTDS): Ranked #8744 globally with a market cap of $1.09 Billion USD ( ILA405.72 Billion ILA).
- EBEST Investment & Securities Co. Ltd (KQ:078020): Ranked #15374 globally with a market cap of $271.26 Million USD ( ₩400.28 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8309 | Aju IB Investment Co. Ltd | KQ:027360 | $1.21 Billion | ₩15000.00 |
| #8731 | Mirae Asset Venture Investment Co. Ltd | KQ:100790 | $1.09 Billion | ₩52400.00 |
| #8744 | Meitav Dash Investments Ltd | TA:MTDS | $1.09 Billion | ILA13440.00 |
| #15374 | EBEST Investment & Securities Co. Ltd | KQ:078020 | $271.26 Million | ₩7840.00 |
Israel China Biotechnology (ICB) Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Israel China Biotechnology (ICB) Ltd's market cap moved from $6.21 Million to $ 25.13 Million, with a yearly change of 9.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA25.13 Million | +202.05% |
| 2025 | ILA8.32 Million | +104.65% |
| 2024 | ILA4.07 Million | +1.15% |
| 2023 | ILA4.02 Million | +375.62% |
| 2022 | ILA844.99K | -86.84% |
| 2021 | ILA6.42 Million | -61.41% |
| 2020 | ILA16.64 Million | +136.57% |
| 2019 | ILA7.03 Million | +47.99% |
| 2018 | ILA4.75 Million | -55.55% |
| 2017 | ILA10.69 Million | -4.66% |
| 2016 | ILA11.21 Million | +80.58% |
| 2015 | ILA6.21 Million | -- |
End of Day Market Cap According to Different Sources
On May 1st, 2026 the market cap of Israel China Biotechnology (ICB) Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.47 Million USD |
| MoneyControl | $19.47 Million USD |
| MarketWatch | $19.47 Million USD |
| marketcap.company | $19.47 Million USD |
| Reuters | $19.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.